Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.46 USD | +4.68% | +8.61% | +96.80% |
Apr. 16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
Apr. 16 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Financials (USD)
Sales 2024 * | 596K | Sales 2025 * | 488K | Capitalization | 31.7M |
---|---|---|---|---|---|
Net income 2024 * | -5M | Net income 2025 * | -7M | EV / Sales 2024 * | 53.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 65 x |
P/E ratio 2024 * |
-5.35
x | P/E ratio 2025 * |
-5.53
x | Employees | 5 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.23% |
1 day | +4.68% | ||
1 week | +8.61% | ||
Current month | -32.23% | ||
1 month | -32.23% | ||
3 months | +64.00% | ||
6 months | +112.07% | ||
Current year | +96.80% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
John Docherty
PSD | President | 53 | 15-04-14 |
George Jurcic
IRC | Investor Relations Contact | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 11-07-07 |
Albert Reese
BRD | Director/Board Member | 74 | 21-01-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 2.46 | +4.68% | 123,838 |
24-04-26 | 2.35 | +7.31% | 172,106 |
24-04-25 | 2.19 | -0.45% | 22,122 |
24-04-24 | 2.2 | -1.79% | 98,910 |
24-04-23 | 2.24 | -1.10% | 53,986 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.80% | 31.7M | |
+26.47% | 664B | |
+25.70% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.42% | 234B | |
+4.71% | 199B | |
-10.10% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- LEXX Stock